myelodysplastic syndromes
Showing NaN - NaN of 101
Acute Myeloid Leukemia, MDS Trial in United States (GLB-001)
Recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
-
Duarte, California
- +3 more
Nov 21, 2023
MDS Trial in Worldwide (Luspatercept)
Not yet recruiting
- Myelodysplastic Syndromes
-
Los Alamitos, California
- +53 more
Sep 13, 2023
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia Trial in United States (drug, procedure, other, radiation)
Not yet recruiting
- Acute Lymphoblastic Leukemia
- +10 more
- Busulfan
- +10 more
-
Jacksonville, Florida
- +5 more
Aug 14, 2023
Acute Myeloid Leukemia, MDS, Chronic Myelomonocytic Leukemia Trial in Worldwide (JNJ-74856665, AZA, VEN)
Active, not recruiting
- Acute Myeloid Leukemia
- +2 more
- JNJ-74856665
- +2 more
-
Birmingham, Alabama
- +22 more
Jan 27, 2023
MDS Trial in Worldwide (Magrolimab, Azacitidine, Placebo)
Active, not recruiting
- Myelodysplastic Syndromes
- Magrolimab
- +2 more
-
Birmingham, Alabama
- +168 more
Dec 7, 2022
MDS, Chronic Myelocytic Leukemia, Acute Myeloid Leukemia Trial in United States (Azacitidine, ASTX030 (cedazuridine +
Recruiting
- Myelodysplastic Syndromes
- +3 more
- Azacitidine
- +2 more
-
Hackensack, New Jersey
- +6 more
Nov 18, 2022
MDS, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute Trial in Worldwide (Azacitidine, Pevonedistat)
Completed
- Myelodysplastic Syndromes
- +2 more
-
Birmingham, Alabama
- +58 more
Aug 24, 2022
Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies Trial
Recruiting
- Relapsed or Refractory Acute Myeloid Leukemia (AML)
- +3 more
-
Birmingham, Alabama
- +26 more
Sep 12, 2022
MDS Trial in Worldwide (Oral Azacitidine, Durvalumab)
Active, not recruiting
- Myelodysplastic Syndromes
- Oral Azacitidine
- Durvalumab
-
New Haven, Connecticut
- +65 more
Aug 19, 2022
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia Trial in United States (drug,
Recruiting
- Acute Lymphoblastic Leukemia
- +7 more
- Busulfan
- +11 more
-
Duarte, California
- +26 more
Aug 11, 2022
AML, MDS, ALL, Adult Trial in Hackensack, New York (SOC + TSC-100, SOC + TSC-101, Control)
Recruiting
- AML
- +2 more
- SOC + TSC-100
- +2 more
-
Hackensack, New Jersey
- +1 more
Aug 11, 2022
Acute Myeloid Leukemia, MDS, Chronic Myelomonocytic Leukemia Trial in Canada, United States (CFI-400945, Azacitidine,
Recruiting
- Acute Myeloid Leukemia
- +5 more
- CFI-400945
- +2 more
-
Duarte, California
- +7 more
Jul 20, 2022
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoma Trial in United States (biological, drug, procedure)
Active, not recruiting
- Acute Lymphoblastic Leukemia
- +3 more
- BPX-501 dose 1
- +5 more
-
Atlanta, Georgia
- +7 more
Jul 10, 2022
MDS Trial in Miami, New York (50 gm CIVI/24 hours x 5 days every 4 week)
Recruiting
- Myelodysplastic Syndromes
- 50 gm CIVI/24 hours x 5 days every 4 week
-
Miami, Florida
- +1 more
Jul 6, 2022
MDS, Myeloproliferative Tumor Trial in United States (Azacitidine Subcutaneous Injection or Intravenous Infusion, Pevonedistat
Active, not recruiting
- Myelodysplastic Syndromes
- Myeloproliferative Neoplasm
- Azacitidine Subcutaneous Injection or Intravenous Infusion
- +2 more
-
Miami, Florida
- +4 more
Jun 20, 2022
Leukemia, Myeloid, Acute, MDS Trial in Worldwide (Azacitidine, Durvalumab)
Active, not recruiting
- Leukemia, Myeloid, Acute
- Myelodysplastic Syndromes
- Azacitidine
- Durvalumab
-
New Haven, Connecticut
- +94 more
Jun 9, 2022
Leukemia, Myeloid, Acute, MDS, Leukemia, Myelomonocytic, Chronic Trial in Worldwide (H3B-8800 (RVT-2001))
Recruiting
- Leukemia, Myeloid, Acute
- +2 more
- H3B-8800 (RVT-2001)
-
Stanford, California
- +26 more
Mar 23, 2022
MDS, Secondary Acute Myeloid Leukemia (AML) Trial in United States (Clofarabine)
Completed
- Myelodysplastic Syndromes
- Secondary Acute Myeloid Leukemia (AML)
-
Chicago, Illinois
- +5 more
Mar 15, 2022
MDS Trial in New York (selinexor (KPT-330))
Completed
- Myelodysplastic Syndromes
- selinexor (KPT-330)
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Feb 11, 2022
Acute Myeloid Leukemia, MDS Trial in United States (CG-806)
Recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
-
Duarte, California
- +9 more
Mar 4, 2022
MDS, Leukemia, Myeloid, Acute, Leukemia, Relapsed Adult Acute Myeloid Trial in New York (CPX-351, Fludarabine, Melphalan)
Active, not recruiting
- Myelodysplastic Syndromes
- +3 more
- CPX-351
- +4 more
-
New York, New YorkWeill Cornell Medical College
Jan 26, 2022